UCL Cancer Institute


Euro Ewing Consortium

The EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC project) was a UCL coordinated collaborative project involving 20 European partners, and was awarded funding through the European Union's Framework Programme 7 (FP7). The EU-funded project ended in September 2019 but the EEC is continuing thanks to the generous support of the Ambalo family and Ewing's Sarcoma Research Trust. The EEC will maintain and expand the collaborative activities established over the six years with the continued aim of improving survival from Ewing sarcoma.

Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases.

The Euro Ewing Consortium is a coalition of clinical study groups bringing together the most active clinicians and scientists in Europe dedicated to improving survival from ES. The EU-funded project supported an integrated programme of investigator-driven, inclusive clinical trials that were rigorously designed, conducted, analysed and reported, and underpinned by complementary embedded translational research. Through collaborative working, the EEC provided ES patients with greater access to clinical trials, allowed efficient acquisition of knowledge and delivered clinically meaningful results that will contribute to improved survival from ES.

Upcoming meetings

  • Cancelled: International Ewing Spring Meeting -  20 April to Tuesday 21 April 2020, University Hospital Essen Campus. 
  • Postponed: International Ewing Sarcoma Research Symposium 2020, Friday 12 June 2020
  • Postponed: SIOP Europe Annual Meeting - new dates 26-30 April 2021, Valencia